Lung transplantation for non-cystic fibrosis bronchiectasis
Lung transplantation (LTx) is a well-established treatment for end-stage pulmonary disease. However, data regarding microbiology and outcome of patients with non-cystic fibrosis bronchiectasis (NCFB) after lung transplantation are limited. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 18, 2016 Category: Respiratory Medicine Authors: Jessica Rademacher, Felix C. Ringshausen, Hendrik Suhling, Jan Fuge, Georg Marsch, Gregor Warnecke, Axel Haverich, Tobias Welte, Jens Gottlieb Source Type: research
Self-reported influenza vaccination and protective serum antibody titers in a cohort of COPD patients
COPD patients are advised vaccination against seasonal influenza, yet few studies have evaluated the protective antibody titers obtained in this patient group. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 18, 2016 Category: Respiratory Medicine Authors: T.M. Eagan, J.A. Hardie, Å. Jul-Larsen, T.B. Grydeland, P.S. Bakke, R.J. Cox Source Type: research
Impact of invasive ventilation on survival when non-invasive ventilation is ineffective in patients with Duchenne muscular dystrophy: A prospective cohort
Many patients with DMD undergo tracheostomy. Tracheostomy is associated with certain complications, however its effect on prognosis is not known. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 18, 2016 Category: Respiratory Medicine Authors: Ghilas Boussaïd, Frédéric Lofaso, Dante Brasil Santos, Isabelle Vaugier, Sandra Pottier, Hélène Prigent, Stéphane Bahrami, David Orlikowski Source Type: research
A bundled care approach to patients with idiopathic pulmonary fibrosis improves transplant-free survival
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with poor prognosis and limited therapeutic options. The 2011 ATS/ERS/JRS/ALAT consensus statement provided a number of recommendations for the management of IPF patients. The primary objective of this study was to determine if “bundling” these recommendations in the management of patients with IPF impacts clinical outcomes. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 18, 2016 Category: Respiratory Medicine Authors: Tejaswini Kulkarni, John Willoughby, Pilar Acosta Lara, Young-il Kim, Rekha Ramachandran, C. Bruce Alexander, Tracy Luckhardt, Victor J. Thannickal, Joao A. de Andrade Source Type: research
Mechanical ventilation in idiopathic pulmonary fibrosis: Unresolved dilemma
We read carefully the article by Barret Rush et al. [1], on using mechanical ventilation (MV) in patients with idiopathic pulmonary fibrosis (IPF) and congratulate the authors on their study. There are, however, some limitations to the study that need considering. First, studies based on administrative databases may involve a larger population but data re-evaluation and validation is more complicated than when compared to studies based on clinical data that involve a smaller group of patients but with more controlled data [2]. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 17, 2016 Category: Respiratory Medicine Authors: Pedro Silva Santos, Cristiana Cruz, Antonio M. Esquinas Tags: Correspondence Source Type: research
Long-term home mechanical ventilation due to obesity hypoventilation syndrome
We read the article by Andreas Palm et al. [1] carefully and congratulate the authors on their study. The prevalence of OHS is increasing alongside with the obesity epidemic, with significant morbidity and mortality associated [2–4]. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 17, 2016 Category: Respiratory Medicine Authors: Pedro Silva Santos, Cristiana Cruz, Antonio M. Esquinas Tags: Correspondence Source Type: research
Mechanical ventilation in idiopathic pulmonary fibrosis: Unresolved dilemma
We read carefully the article by Barret Rush et al. [1], on using mechanical ventilation (MV) in patients with idiopathic pulmonary fibrosis (IPF) and congratulate the authors on their study. There are, however, some limitations to the study that need considering. First, studies based on administrative databases may involve a larger population but data re-evaluation and validation is more complicated than when compared to studies based on clinical data that involve a smaller group of patients but with more controlled data [2]. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 17, 2016 Category: Respiratory Medicine Authors: Pedro Silva Santos, Cristiana Cruz, Antonio M. Esquinas Tags: Editorial Source Type: research
Long-term home mechanical ventilation due to obesity hypoventilation syndrome
We read the article by Andreas Palm et al. [1] carefully and congratulate the authors on their study. The prevalence of OHS is increasing alongside with the obesity epidemic, with significant morbidity and mortality associated [2–4]. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 17, 2016 Category: Respiratory Medicine Authors: Pedro Silva Santos, Cristiana Cruz, Antonio M. Esquinas Tags: Editorial Source Type: research
Presence of rhinovirus in the respiratory tract of adolescents and young adults with asthma without symptoms of infection
This study aimed to determine the presence of respiratory viruses, without symptoms of infection, in the airways of young asthmatics as compared to healthy controls. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 13, 2016 Category: Respiratory Medicine Authors: L. Öhrmalm, A. Malinovschi, M. Wong, P. Levinson, C. Janson, K. Broliden, K. Alving Source Type: research
Assessing biomarkers in a real-world severe asthma study (ARIETTA)
The prognostic value of asthma biomarkers in routine clinical practice is not fully understood. ARIETTA (NCT02537691) is an ongoing, prospective, longitudinal, international, multicentre real-world study designed to assess the relationship between asthma biomarkers and disease-related health outcomes. The trial aims to enrol and follow for 52 weeks approximately 1200 severe asthma patients from approximately 160 sites in more than 20 countries. Severe asthmatics, treated with daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 s controller medication are to be included. (Sourc...
Source: Respiratory Medicine CME - April 13, 2016 Category: Respiratory Medicine Authors: Roland Buhl, Stephanie Korn, Andrew Menzies-Gow, Michel Aubier, Kenneth R. Chapman, Giorgio W. Canonica, César Picado, Nicolas Martin, Ramon Aguiar Escobar, Stephan Korom, Nicola A. Hanania Source Type: research
Characterisation of fatigue and its substantial impact on health status in a large cohort of patients with chronic pulmonary aspergillosis (CPA)
Fatigue is a prominent disabling symptom in several pulmonary diseases. Its impact on health status in patients with chronic pulmonary aspergillosis (CPA) has not been investigated. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - April 1, 2016 Category: Respiratory Medicine Authors: Khaled Al-shair, Eavan G. Muldoon, Julie Morris, Graham T. Atherton, Chris Kosmidis, David W. Denning Source Type: research
Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease
Treatment with long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) for chronic obstructive pulmonary disease (COPD) is standard, but response varies. We investigated genetic association with treatment response to umeclidinium (UMEC, a LAMA), vilanterol (VI, a LABA), and combination therapy. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - March 30, 2016 Category: Respiratory Medicine Authors: Lynn Condreay, Lingkang Huang, Elizabeth Harris, Jean Brooks, John H. Riley, Alison Church, Soumitra Ghosh Tags: Short communication Source Type: research
The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study)
This multicentre, double-blind, randomised, placebo-controlled, crossover study aimed to determine the dose-response of the long-acting muscarinic antagonist (LAMA) glycopyrronium bromide (GB) when added to beclometasone dipropionate plus formoterol fumarate (BDP/FF) in patients with COPD.Patients received extrafine GB 12.5, 25 or 50μg twice daily (BID) or placebo for 7 days via pressurised metered dose inhaler (pMDI), and extrafine BDP/FF via pMDI throughout the study. The primary objective was to demonstrate superiority of GB plus BDP/FF versus BDP/FF in terms of FEV1 area under the curve from 0–12 hours (AUC0-12h) on...
Source: Respiratory Medicine CME - March 24, 2016 Category: Respiratory Medicine Authors: Dave Singh, Winfried Schröder-Babo, Géraldine Cohuet, Annamaria Muraro, Françoise Bonnet-Gonod, Stefano Petruzzelli, Martin Hoffmann, Zenon Siergiejko, the TRIDENT study investigators Source Type: research
Gender inequalities in COPD decision-making in primary care
COPD is a frequent severe illness that increasingly affects females. Gender inequalities have been reported in COPD care. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - March 23, 2016 Category: Respiratory Medicine Authors: Ana Delgado, Lorena Saletti-Cuesta, Luis Andrés López-Fernández, Natalia Gil-Garrido, Juan de Dios Luna del Castillo Source Type: research
Long-term safety of glycopyrrolate: a randomized study in patients with moderate-to-severe COPD (GEM3)
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the United States. Long-acting muscarinic antagonists (LAMAs) are a class of medications used as maintenance therapy for COPD. The GEM3 (Glycopyrrolate Effect on syMptoms and lung function) study assessed the long-term safety and efficacy of a LAMA, glycopyrrolate (GLY) 15.6 μg twice daily (b.i.d.), compared with an approved long-acting β2-agonist (LABA), indacaterol (IND) 75 μg once daily (q.d.) in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation. (Source: Respiratory Medicine CME)
Source: Respiratory Medicine CME - March 21, 2016 Category: Respiratory Medicine Authors: Donald A. Mahler, Alex H. Gifford, Aditi Satti, Nicola Jessop, Joerg H. Eckert, Peter D'Andrea, Fernando Mota, Rudrani Banerjee Source Type: research
